Company intelligence / Profile preview
ImmunOs Therapeutics
Schlieren, Zurich, Switzerlandimmunostherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
ImmunOs Therapeutics has developed a proprietary HLA-based platform to generate first-in-class biologic therapeutics targeting both cancer and autoimmune diseases. Their lead candidate IOS‑1002 has shown promising preclinical results as both a monotherapy and in combination with existing cancer treatments. The company’s approach uniquely addresses multiple innate immune system targets via single molecules and aims to stimulate both innate and adaptive immunity against tumors while also developing antibodies for autoimmune disease modulation. A clinical trial collaboration with Merck further validates their approach.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Biologic therapeutics (novel immunomodulatory proteins)AntibodiesFusion proteins
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Merck & Co. – clinical trial collaboration in oncology/immunotherapy space.
Beyond the preview
Go deeper on ImmunOs Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunOs Therapeutics.